Xeris Biopharma Holdings Inc

XERS remains in a Stage 2 advance within its long-term uptrend, driven by an active Parabola pattern signaling strong acceleration. With price extended above rising EMAs and RSI in extreme overbought territory, immediate bullish entries are unfavorable. Preferred engagement is deferred: look for pullbacks into the rising EMA zone as structurally favorable entry points, while remaining vigilant for potential transition risk to Stage 3 distribution.

• ↑Q1 2026 net product revenue rose 43% YoY to $82M
• ↑Recorlev sales surged 95%, with $50M in Q1 revenue
• ↓Negative book-to-price signals potential overvaluation and downside